Recurrent Fusion Genes in Leukemia: An Attractive Target for Diagnosis and Treatment

Current Genomics
Yuhui WangYan Jin

Abstract

Since the first fusion gene was discovered decades ago, a considerable number of fusion genes have been detected in leukemia. The majority of them are generated through chromosomal rearrangement or abnormal transcription. With the development of techniques, high-throughput sequencing method makes it possible to detect fusion genes systematically in multiple human cancers. Owing to their biological significance and tumor-specific expression, some of the fusion genes are attractive diagnostic tools and therapeutic targets. Tyrosine kinase inhibitors (TKI) targeting BCR-ABL1 fusions have been widely used to treat CML. The combination of ATRA and ATO targeting PML-RARA fusions has proven to be effective in acute promyelocytic leukemia (APL). Moreover, therapy with high dose cytarabine (HDAC) has significantly improved the prognosis of core binding factor (CBF) acute myeloid leukemia (AML) patients. Therefore, studies on fusion genes may benefit patients with leukemia by providing more diagnostic markers and therapies in the future. The presented review focuses on the history of fusion genes, mechanisms of formation, and treatments against specific fusion genes in leukemia.

Citations

Jul 7, 2019·Nature Reviews. Cancer·Christof C SmithJonathan S Serody
Mar 4, 2021·NPJ Precision Oncology·Ianthe A E M van BelzenJayne Y Hehir-Kwa
May 1, 2021·Journal of Clinical Medicine·Shicheng YangSrinivas Sridhar
May 5, 2021·Leukemia & Lymphoma·Shady Adnan-AwadSatu Mustjoki
May 25, 2021·Blood Cancer Discovery·Aline RennevilleBenjamin L Ebert
Jul 8, 2021·Cancer Discovery·Aline RennevilleBenjamin L Ebert
Jul 25, 2021·International Journal of Molecular Sciences·Alvina I KhamidullinaAlexandra V Bruter
Aug 24, 2021·The Journal of Pediatric Pharmacology and Therapeutics : JPPT : the Official Journal of PPAG·Sara D A AngioneClinton F Stewart

❮ Previous
Next ❯

Methods Mentioned

BETA
PCR

Related Concepts

Related Feeds

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.